Representational image
Bhubaneswar: The World Health Organization (WHO) has recommended two new drugs – Eli Lilly & Co.’s rheumatoid arthritis drug and GlaxoSmithKline Plc’s monoclonal antibody – for treating patients with COVID-19.
According to the WHO Guideline Development Group, Lilly’s Baricitinib drug is “strongly recommended” for patients with severe or critical disease in combination with corticosteroids. It is a Janus kinase (JAK) inhibitor- a class of drugs used to treat autoimmune conditions, blood and bone marrow cancers, and rheumatoid arthritis.
The recommendation is based on “moderate certainty evidence” that it improves survival and reduces the need for ventilation.
The experts have advised against the use of two other JAK inhibitors (ruxolitinib and tofacitinib) in such cases.
The WHO has recommended the use of a monoclonal antibody, known as Sotrovimab, in non-severe cases. The drug should only be administered to patients at the highest risk of hospitalisation, such as the elderly, people with immunodeficiencies or chronic diseases such as diabetes.
Last year, the WHO had approved Regeneron Pharmaceuticals Inc’s monoclonal antibody to treat COVID patients.
Bhubaneswar: In a significant stride towards advancing economic growth in the state, the Odisha government…
Hyderabad: ‘Baahubali’ actor Prabhas has signed a three-movie deal with Hombale Films, the makers of…
Berhampur: After theft from famous Tara Tarini shrine in Odisha’s Ganjam, burglars decamped with a…
Mumbai: Actress Athiya Shetty and Team India cricketer KL Rahul will welcome a new member…
Mumbai: Chief Election Commissioner (CEC) Rajiv Kumar on Friday came down heavily on political leaders…
Bhubaneswar: The Capital Region Urban Transport (CRUT), a public transit agency in Odisha, on Friday…
Mumbai: Over the years, female actresses have often outshone their male confreres at the domestic…
Bhubaneswar: War of words between the ruling Bharatiya Janata Party (BJP) and opposition Biju Janata…